Mycobacterium Citations List: February 2025

Literature Citations

1. Synthesis and Antimycobacterial Assays of Some New Ethambutol Analogs. Abdelaziz, R., M. Dube, L. Mann, A. Richter, D. Robaa, N. Reiling, M. Abdel-Halim, and P. Imming. Molecules, 2025. 30(3). PMID[39942704]. PMCID[PMC11820526].
[PubMed]. TB_02_2025.

2. In Vitro and In Silico Exploration of Newly Synthesized Triazolyl-isonicotinohydrazides as Potent Antitubercular Agents. Bakale, R.D., P.S. Phatak, S.S. Rathod, P.B. Choudhari, E.M. Rekha, D. Sriram, R.S. Kulkarni, and K.P. Haval. Journal of Biomolecular Structure and Dynamics, 2025. 43(3): p. 1372-1391. PMID[38079301].
[PubMed]. TB_02_2025.

3. A Molecular Hybridization Approach to Design and Study the In Vitro and In Silico Properties of N-phenyl-4-oxo-butanamide Derivatives. Bothsa, S.S., H. Veeravarapu, S. Guruvelli, S. Singarapalle, T. Prasanthi, and M.K.K. Muthyala. Indian Journal of Chemistry, 2024. 63(9): p. 847-854. ISI[001419607800001].
[WOS]. TB_02_2025.

4. One-pot Synthesis and Antitubercular Activity of Imidazo[2,1-b]thiazol-1h-pyrazolylphosphonates. Chirra, N., V. Shanigarapu, B. Sridhar, and S. Kantevari. Asian Journal of Organic Chemistry, 2025. e202400724. ISI[001407045800001].
[WOS]. TB_02_2025.

5. A Systematic Approach to Discover New Natural Product Scaffolds Using Database-Derived Relative Mass Spectral Defects and Molecular Networking. Cho, H.M., E. Boccia, R. Rajwani, R.D. O'Connor, H. Boshoff, C. Barry, 3rd, G. Bifulco, and C.A. Bewley. JACS Au, 2025. 5(2): p. 653-665. PMID[40017746]. PMCID[PMC11862952].
[PubMed]. TB_02_2025.

6. Determining the Antimycobacterial Action of Rottlerin against Mycobacterium Species and Toxicity, Antioxidant Properties, and Therapeutic Target Affinity of Rottlerin. Damasceno, J.L., M.B. Santiago, R.P. Menezes, T.R. Esperandim, S.D. Ozelin, M. Silva, U.R. Landaeta, D.C. Tavares, L.C.S. Cunha, E.A.V. Ferro, T.A.M. Fernandes, and C.H.G. Martins. Current Microbiology, 2025. 82(4): 147. PMID[39982530].
[PubMed]. TB_02_2025.

7. Preclinical Evaluation of Selene-ethylenelacticamides in Tuberculosis: Effects against Active, Dormant, and Resistant Mycobacterium tuberculosis and In Vitro Toxicity Investigation. de Sousa, N.F., M.E.G. de Freitas, M.G.S. Sidrônio, H.D. Souza, A. Czeczot, M. Perelló, G.F. Fiss, L. Scotti, D.A.M. de Araújo, J.M. Barbosa Filho, C.V. Bizarro, P. Machado, L.A. Basso, F.J.B. Mendonça-Junior, P.F. de Athayde Filho, M.T. Scotti, and V.S. Rodrigues-Junior. Microorganisms, 2025. 13(2). PMID[40005762]. PMCID[PMC11858155].
[PubMed]. TB_02_2025.

8. Exploring Antimycobacterial Potential: Safety Evaluation and Active Compound Isolation from Gymnopilus Junonius. Didloff, J., G.J. Boukes, M.N. Nyambe, D.R. Beukes, M.S. Lerata, V. Vilane, M. Lee, S. Govender, and M. van de Venter. Antibiotics, 2025. 14(2). PMID[40001422]. PMCID[PMC11851804].
[PubMed]. TB_02_2025.

9. In Vitro Activity of Rifampicin, Rifapentine and Rifabutin in Combination with Their 25-deacetyl-metabolites against Various Mycobacterium tuberculosis Lineages. Genestet, C., C. Bourg, E. Hodille, O. Bahuaud, F. Ader, S. Goutelle, and O. Dumitrescu. Annals of Clinical Microbiology and Antimicrobials, 2025. 24(1): 16. PMID[40022145]. PMCID[PMC11871726].
[PubMed]. TB_02_2025.

10. Exploration of Novel Isoniazid Embedded 1,3,4-oxadiazole Hybrids as Anti-TB, Antioxidant, and Cox Inhibitors: Synthesis, Spectral Analysis, and Molecular Modeling Studies. Jisha, S.P., G.Y. Nagesh, P. Karunakar, G. Nidhi, B.T. Sridhar, and S.M. Basavarajaiah. Journal of the Iranian Chemical Society, 2025. ISI[001408563500001].
[WOS]. TB_02_2025.

11. Efficacy of Nintedanib as a Host-directed Therapy Candidate in the Treatment of Tuberculosis. Li, X., X. Qi, B. Wang, L. Fu, X. Chen, X. Luo, X. Chen, and Y. Lu. J Journal of Antimicrobial Chemotherapy, 2025. 80(2): p. 452-464. PMID[39656809].
[PubMed]. TB_02_2025.

12. Metabolically Stable Adenylation Inhibitors of Biotin Protein Ligase as Antibacterial Agents. Liu, Q., C.A. Engelhart, J.B. Wallach, D. Tiwari, P. Ge, A. Manna, S. Panda, W.M. McCue, T.Y. Wong, S. Sharma, Y.P. Jayasinghe, J. Fuller, D.R. Ronning, M.R. Bockman, A. Cheung, V. Dartois, M.D. Zimmerman, D. Schnappinger, and C.C. Aldrich. Journal of Medicinal Chemistry, 2025. 68(3): p. 3065-3087. PMID[39823202].
[PubMed]. TB_02_2025.

13. Anti-mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated Linkers. Mitton-Fry, M.J., J.E. Cummings, Y. Lu, J.F. Armenia, J.A.W. Byl, A.A. Oviatt, A.A. Bauman, G.T. Robertson, N. Osheroff, and R.A. Slayden. ACS Infectious Diseases, 2025. 11(2): p. 474-482. PMID[39792935]. PMCID[PMC11834967].
[PubMed]. TB_02_2025.

14. Structural Analysis, In Vitro Anti-tubercular Activities, and In Silico ADMET Evaluation of Ethyl 7-methoxy-3-(4-substituted benzoyl)indolizine-1-carboxylates. Nagdeve, R.D., J.S. Thakur, S. Chandrashekharappa, P.K. Mondal, P.K. Deb, M. Polentarutti, K.M. Bairagi, G. Rakshit, O.I. Alwassil, M. Pillay, K.N. Venugopala, and S.K. Nayak. CrystEngComm, 2025. ISI[001406657500001].
[WOS]. TB_02_2025.

15. Antimycobacterial Activities of the Zanthoxylum leprieurii Metabolite Adubangoamide and Non-natural Fagaramide Analogues. Oloya, B., J. Namukobe, M. Krüger, W. Ssengooba, E. Sperlich, G. Kwesiga, K. Komakech, M. Heydenreich, R. Byamukama, and B. Schmidt. Journal of Natural Products, 2025. 88(2): p. 530-536. PMID[39931869].
[PubMed]. TB_02_2025.

16. Enhancing the Antimycobacterial Efficacy of Pyridine-4-carbohydrazide: Linkage to Additional Antimicrobial Agents Via Oxocarboxylic Acids. Pflégr, V., K. Konečná, J. Stolaříková, J. Ősterreicher, O. Janďourek, and M. Krátký. RSC Medicinal Chemistry, 2025. 16(2): p. 767-778. PMID[39568598]. PMCID[PMC11575622].
[PubMed]. TB_02_2025.

17. Catalyst and Solvent-free, Ultrasound Promoted Rapid Protocol for the One-pot Synthesis of Benzothiazol-2-yl(piperazin-1-yl)methanones: Design, Synthesis, X-ray Crystallography, In Vitro, and In Silico Studies. Qadir, T., K. Jangid, W. Safir, S.A. Kanth, K. Ahmed, K.N. Sheikh, W.A. Shah, and P.K. Sharma. Journal of Molecular Structure, 2025. 1327: 141074. ISI[001412378200001].
[WOS]. TB_02_2025.

18. Design, Synthesis, and Molecular Docking of Novel Benzothiazinone Derivatives as DprE1 Inhibitors with Potential Antitubercular Activities. Raghu, M.S., A.Y. Jassim, K.Y. Kumar, F. Alharethy, M.K. Prashanth, and B.H. Jeon. Russian Journal of Bioorganic Chemistry, 2025. 51(1): p. 65-78. ISI[001421221900008].
[WOS]. TB_02_2025.

19. A Green One-pot Three Component Synthesis of Thiazolidine-2,4-dione Based Bisspirooxindolo-pyrrolidines with [Bmim]BF(4): Their in Vitro and in Silico Anti-TB Studies. Rukyanaik, V., R.K. Gamidi, J. Kumari, D. Sriram, and S. Basavoju. Molecular Diversity, 2025. 29(1): p. 303-317. PMID[38789853].
[PubMed]. TB_02_2025.

20. Design, Synthesis, and Antitubercular Evaluation of Piperazinyl-pyrazolyl-2-hydrazinyl Thiazole Derivatives: Experimental, DFT and Molecular Docking Insights. Sable, Y.R., V.A. Adole, E.A. Pithawala, and R.D. Amrutkar. Journal of Sulfur Chemistry, 2025. ISI[001423021000001].
[WOS]. TB_02_2025.

21. Spectroscopic Studies on Structurally Modified Anthraquinone Azo Hydrazone Tautomer: Theoretical and Experimental Approach. Shekharagouda, P., G.P. Mamatha, G. Nagaraju, C. Krishnamurthy, S. Gouthaman, B.A. Al-Asbahi, N.M. Al-Hada, and L. Naik. Journal of Fluorescence, 2025. 35(2): p. 819-833. PMID[38183589].
[PubMed]. TB_02_2025.

22. Durlobactam in Combination with Β-lactams to Combat Mycobacterium abscessus. Shin, E., K.M. Dousa, M.A. Taracila, C.R. Bethel, M. Nantongo, D.C. Nguyen, C. Akusobi, S.G. Kurz, M.S. Plummer, C.L. Daley, S.M. Holland, E.J. Rubin, J.B. Bulitta, W.H. Boom, B.N. Kreiswirth, and R.A. Bonomo. Antimicrobial Agents and Chemotherapy, 2025. 69(2): e0117424. PMID[39714147]. PMCID[PMC11823594].
[PubMed]. TB_02_2025.

23. Fl058, a Novel Β-lactamase Inhibitor, Increases the Anti-mycobacterium abscessus Activity of Imipenem. Tan, Z., Y. Lin, J. Fan, Y. Jia, S. Zheng, X. Wang, C. Gao, Z. Zhang, B. Li, and H. Chu. International Journal of Antimicrobial Agents, 2025. 65(2): 107414. PMID[39710142].
[PubMed]. TB_02_2025.

24. Hydrazide-hydrazone Derivatives and Their Antitubercular Activity. Thorat, B.R., S.N. Mali, U.M. Shah, A. Garg, R. Agrawal, S.A. Arvindekar, J.N. Cruz, M.S. de Oliveira, A.B. Shaik, and B.V.S. Lokesh. Russian Journal of Bioorganic Chemistry, 2025. 51(1): p. 35-52. ISI[001421221900017].
[WOS]. TB_02_2025.

25. Screening, Discovery, and Optimization of the Natural Antitubercular Chlorflavonin from a Marine-derived Fungal Library. Wang, C.F., W.H. Wang, Y. Xu, Q. Zhang, M.Y. Wei, Y.C. Gu, T.Y. Xu, and C.L. Shao. Journal of Natural Products, 2025. 88(2): p. 522-529. PMID[39813394].
[PubMed]. TB_02_2025.

26. Development of Novel Sulfonamide-based Pyrazole-clubbed Pyrazoline Derivatives: Synthesis, Biological Evaluation, and Molecular Docking Study. Zala, M., J.J. Vora, V.M. Khedkar, A.H. Almalki, S. Tivari, and R. Jatvada. ACS Omega, 2025. 10(7): p. 7120-7130. PMID[40028071]. PMCID[PMC11866009].
[PubMed]. TB_02_2025.

Patent Citations

27. Benzo[de]isoquinoline-1,3-dione based compound and use thereof. Parkesh, R., and S. Chhabra. Patent. 2025. WO2024-IN514662025032611: 35pp.
[Patent]. TB_02_2025.

28. Preparation of (E)-1-(2-(4-substituted-phenyl)-2-oxoethyl)-4-((hydroxyimino)methyl)pyridinium bromides as antitubercular agents. Venugopala, K.N., S. Chandrashekharappa, M. Pillay, P.K. Deb, and R. Venugopala. Patent. 2025. US2024-74394612215082: 13pp.
[Patent]. TB_02_2025.

29. Preparation of 1-(2-(substituted phenyl)-2-oxoethyl)-4-methylpyridin-1-ium bromide as anti-tubercular agents. Venugopala, K.N., M. Pillay, P.K. Deb, M.A. Morsy, S. Chandrashekarappa, and B. Aldhubiab. Patent. 2025. US2023-37740712227480: 11pp.
[Patent]. TB_02_2025.